- Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement
- Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade
- Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies
- New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes
Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies
- Sano Genetics launches ‘Light The Way’, offering peer support, DNA testing, genetic counseling and education to those diagnosed with or experiencing symptoms of ALS, and those at risk of genetic ALS due to their family history.
- Around one in five ALS cases are now thought to be genetic; 40+ genes have been linked to the disease thanks to new discoveries funded in part by the 2014 ALS ice bucket challenge.*
- Knowing their genetic risk could offer relief to many, while those who test positive may be able to access newly approved therapies, clinical trials and observational studies like Beacon, which charts the psychological impact of ALS genetic testing.
£330K grant awarded to support and engage patients at risk of MND/ALS, and track the psychological impact of genetic testing.
- Sano raises $11 million in Series A funding round led by MMC Ventures
- New funding will support the team to grow and further its mission to accelerate personalised medicine research
- Sano aims to address the challenge of a decades-long, costly drug development process so that new treatments can reach patients faster
- Sano Genetics supports personalised medicine research by increasing participation in clinical trials and guiding patients through the process
- Half of clinical trials are delayed due to recruitment issues and 85% fail as they can’t retain enough participants
- Seed round will fund free at-home DNA testing kits for 3,000 people affected by Long Covid, further development of its tech platform and team expansion